6. References
1. Vahratian, A., et al., Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome in Adults: United States, 2021-2022. NCHS Data Brief,
2023(488): p. 1-8.2. Renz-Polster, H. and C. Scheibenbogen,[Post-COVID syndrome with fatigue and exercise intolerance:
myalgic encephalomyelitis/chronic fatigue syndrome]. Inn Med
(Heidelb), 2022. 63 (8): p. 830-839.3. Nacul, L., et al.,European Network on Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service
Provision, and Care of People with ME/CFS in Europe. Medicina, 2021.57 (5): p. 510.4. Lim, E.J., et al., Systematic review and
meta-analysis of the prevalence of chronic fatigue syndrome/myalgic
encephalomyelitis (CFS/ME). J Transl Med, 2020. 18 (1): p.
100.5. Lutz, L., et al., Evaluation of Immune Dysregulation in an
Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome. Biomolecules, 2021. 11 (9): p. 1359.6. Rasa,
S., et al., Chronic viral infections in myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). Journal of
Translational Medicine, 2018. 16 (1): p. 268.7. Untersmayr, E.,
et al., Immune Mechanisms Underpinning Long COVID: Collegium
Internationale Allergologicum Update 2024. Int Arch Allergy Immunol,
2024. 185 (5): p. 489-502.8. Altmann, D.M., et al., The
immunology of long COVID. Nature Reviews Immunology, 2023.9.
Nagy-Szakal, D., et al., Fecal metagenomic profiles in subgroups
of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome, 2017. 5 (1): p. 44.10. Kratzer, B., et al.,Differential decline of SARS-CoV-2-specific antibody levels,
innate and adaptive immune cells, and shift of Th1/inflammatory to Th2
serum cytokine levels long after first COVID-19. Allergy, 2024.11.
Tsounis, E.P., et al., Intestinal barrier dysfunction as a key
driver of severe COVID-19. World J Virol, 2023. 12 (2): p.
68-90.12. Schwarze, J., et al., Latency and persistence of
respiratory syncytial virus despite T cell immunity. Am J Respir Crit
Care Med, 2004. 169 (7): p. 801-5.13. Kim, T.S., et al.,Antigen persistence and the control of local T cell memory by
migrant respiratory dendritic cells after acute virus infection. Journal of Experimental Medicine, 2010. 207 (6): p.
1161-1172.14. Choudhury, A., et al., Gastrointestinal
manifestations of long COVID: A systematic review and meta-analysis. Therap Adv Gastroenterol, 2022. 15 : p. 17562848221118403.15.
Committee on the Diagnostic Criteria for Myalgic
Encephalomyelitis/Chronic Fatigue, S., P. Board on the Health of Select,
and M. Institute of, The National Academies Collection: Reports
funded by National Institutes of Health , in Beyond Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness .
2015, National Academies Press (US) Copyright 2015 by the National
Academy of Sciences. All rights reserved.: Washington (DC).16. Corman,
V.M., et al., Detection of 2019 novel coronavirus (2019-nCoV) by
real-time RT-PCR. Eurosurveillance, 2020. 25 (3): p.
2000045.17. Vietzen, H., et al., Deletion of the NKG2C receptor
encoding KLRC2 gene and HLA-E variants are risk factors for severe
COVID-19. Genet Med, 2021. 23 (5): p. 963-967.18. Cervia, C.,
et al., Immunoglobulin signature predicts risk of post-acute
COVID-19 syndrome. Nature Communications, 2022. 13 (1): p.
446.19. Gupta, A. and G.S. Gupta, Status of mannose-binding lectin
(MBL) and complement system in COVID-19 patients and therapeutic
applications of antiviral plant MBLs. Molecular and Cellular
Biochemistry, 2021. 476 (8): p. 2917-2942.20. Ali, Y.M., et al.,Lectin Pathway Mediates Complement Activation by SARS-CoV-2
Proteins. Frontiers in Immunology, 2021. 12 .21. Kedor, C., et
al., A prospective observational study of post-COVID-19 chronic
fatigue syndrome following the first pandemic wave in Germany and
biomarkers associated with symptom severity. Nature Communications,
2022. 13 (1): p. 5104.22. Jack, D.L., et al.,Mannose-binding lectin regulates the inflammatory response of
human professional phagocytes to Neisseria meningitidis serogroup B. J
Infect Dis, 2001. 184 (9): p. 1152-62.23. Chohan, K., et al.,A review of respiratory manifestations and their management in
Ehlers-Danlos syndromes and hypermobility spectrum disorders. Chron
Respir Dis, 2021. 18 : p. 14799731211025313.24. Thwaites, P.A.,
P.R. Gibson, and R.E. Burgell, Hypermobile Ehlers-Danlos syndrome
and disorders of the gastrointestinal tract: What the gastroenterologist
needs to know. J Gastroenterol Hepatol, 2022. 37 (9): p.
1693-1709.25. Lakhani, C.M., et al., Repurposing large health
insurance claims data to estimate genetic and environmental
contributions in 560 phenotypes. Nat Genet, 2019. 51 (2): p.
327-334.26. Kendler, K.S., et al., A distinctive profile of family
genetic risk scores in a Swedish national sample of cases of
fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome
compared to rheumatoid arthritis and major depression. Psychol Med,
2023. 53 (9): p. 3879-3886.27. Albright, F., et al.,Evidence for a heritable predisposition to Chronic Fatigue
Syndrome. BMC Neurol, 2011. 11 : p. 62.28. Cevik, M., et al.,SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration
of viral shedding, and infectiousness: a systematic review and
meta-analysis. Lancet Microbe, 2021. 2 (1): p. e13-e22.29.
Rohrhofer, J., et al., Association between Epstein-Barr-Virus
reactivation and development of Long-COVID fatigue. Allergy, 2023.78 (1): p. 297-299.30. Zollner, A., et al., Postacute
COVID-19 is Characterized by Gut Viral Antigen Persistence in
Inflammatory Bowel Diseases. Gastroenterology, 2022. 163 (2):
p. 495-506.e8.31. Gaebler, C., et al., Evolution of antibody
immunity to SARS-CoV-2. Nature, 2021. 591 (7851): p.
639-644.32. Jason, L.A. and J.A. Dorri, Predictors of impaired
functioning among long COVID patients. Work, 2023. 74 (4): p.
1215-1224.33. Sudre, C.H., et al., Attributes and predictors of
long COVID. Nat Med, 2021. 27 (4): p. 626-631.34. Gang, J., et
al., Microbiota and COVID-19: Long-term and complex influencing
factors. Front Microbiol, 2022. 13 : p. 963488.35. Kitchens,
R.L. and P.A. Thompson, Modulatory effects of sCD14 and LBP on
LPS-host cell interactions. J Endotoxin Res, 2005. 11 (4): p.
225-9.36. Rohrhofer, J., et al., Immunological Patient
Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Clinical Medicine, 2024. 13 (1): p. 275.37.
Laugerette, F., et al., Postprandial Endotoxin Transporters LBP
and sCD14 Differ in Obese vs. Overweight and Normal Weight Men during
Fat-Rich Meal Digestion. Nutrients, 2020. 12 (6).38. Lau, E.,
et al., The role of I-FABP as a biomarker of intestinal barrier
dysfunction driven by gut microbiota changes in obesity. Nutr Metab
(Lond), 2016. 13 : p. 31.39. Szymanska, E., et al., Fecal
Zonulin as a Noninvasive Biomarker of Intestinal Permeability in
Pediatric Patients with Inflammatory Bowel Diseases-Correlation with
Disease Activity and Fecal Calprotectin. J Clin Med, 2021.10 (17).40. Chelakkot, C., J. Ghim, and S.H. Ryu,Mechanisms regulating intestinal barrier integrity and its
pathological implications. Experimental & Molecular Medicine, 2018.50 (8): p. 1-9.41. Hodzic, Z., et al., IL-33 and the
intestine: The good, the bad, and the inflammatory. Cytokine, 2017.100 : p. 1-10.42. Wu, W.H., et al., Interleukin-1β
secretion induced by mucosa-associated gut commensal bacteria promotes
intestinal barrier repair. Gut Microbes, 2022. 14 (1): p.
2014772.